Table 2.

Baseline characteristics of the study populations stratified by diabetes status.

	Group I nT2DM N = 264	Group I T2DM n = 68	Group II nT2DM N = 322	Group II T2DM n = 103	Group III nT2DM n = 267	Group III T2DM n = 214
Age, years	60 ± 11	60 ± 12	64 ± 10	65 ± 10	67 ± 10	67 ± 10
Male sex (%)	39	32	62	65	70	75
T2DM duration (years)	N/A	5 ± 4	N/A	8 ± 10	N/A	11 ± 8
Hypertension (%)	48	68	62	78	80	91
Smoking (%)	46	47	52	61	84	78
Body mass index (kg/m²)	27 ± 4	31 ± 6	27 ± 4	29 ± 5	26 ± 4	28 ± 4
HbA1c (%)	5.6 ± 0.4	7.1 ± 1.7	5.7 ± 0.3	7.2 ± 1.1	5.6 ± 0.4	7.1 ± 1.3
Triglycerides (mg/dl)	131 ± 78	166 ± 119	136 ± 85	182 ± 134	140 ± 86	180 ± 132
Total cholesterol (mg/dl)	213 ± 44	198 ± 47	210 ± 44	200 ± 45	185 ± 42	173 ± 49
LDL-cholesterol (mg/dl)	135 ± 36	119 ± 38	135 ± 38	124 ± 38	109 ± 35	98 ± 43
HDL-cholesterol (mg/dl)	60 ± 19	52 ± 16	57 ± 16	50 ± 14	56 ± 18	48 ± 16
Systolic blood pressure (mm Hg)	133 ± 19	139 ± 21	137 ± 19	140 ± 21	139 ± 22	142 ± 26
Diastolic blood pressure (mm Hg)	81 ± 10	84 ± 11	82 ± 10	82 ± 12	79 ± 11	79 ± 13
Statin use (%)	25	35	38	47	66	75
ACE inhibitors / AT II RBA (%)	26	47	39	51	46	70
Beta receptor blocking agents (%)	37	58	51	48	36	47
Aspirin or clopidogrel (%)	63	55	64	74	85	85
eGFR-EPI (ml/min/1.73m2)	83	80	74	68	72	68
CKD (%) (EPI eGFR < 60 ml/min/1.73 m²)	13	25	14	26	14	22

Data are shown for Group I, Group II and Group III as means ± SD if not denoted otherwise.

ACE angiotensin converting enzyme, ATII RBA angiotensin II receptor blocking agents, HbA1c hemoglobin A1c, HDL high density lipoprotein, LDL low density lipoprotein, T2DM type 2 diabetes mellitus, prior MI prior myocardial infarction, GFR-EPI glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration formula; CKD chronic kidney disease. To convert values for triglycerides to mmol/L multiply by 0.0113 and to convert values for total cholesterol, LDL cholesterol or HDL cholesterol to mmol multiply by 0.0259.